Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration.
Angiogenesis Inhibitors
/ therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
/ therapeutic use
Humans
Intraocular Pressure
Ranibizumab
/ therapeutic use
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
Retrospective Studies
Vascular Endothelial Growth Factor A
Wet Macular Degeneration
/ drug therapy
Aflibercept
Anti-vascular endothelial growth factor
Bevacizumab
Intraocular pressure
Wet age-related macular degeneration
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
28 Aug 2021
28 Aug 2021
Historique:
received:
07
01
2021
accepted:
14
08
2021
entrez:
29
8
2021
pubmed:
30
8
2021
medline:
1
9
2021
Statut:
epublish
Résumé
To evaluate the incidence of sustained elevation of intraocular pressure (SE-IOP) associated with intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) bevacizumab and aflibercept in patients with wet age-related macular degeneration (wAMD). A retrospective cohort study consisting of 120 eyes from 120 patients with anti-VEGF treatment for wAMD. Three different anti-VEGF groups were considered: i) 71 cases receiving bevacizumab only, ii) 49 cases receiving bevacizumab before switch to aflibercept, iii) 49 cases after switch to aflibercept. 120 uninjected fellow eyes served as controls. SE-IOP was defined as an increase from baseline ≥5 mmHg on 2 consecutive follow-up visits. The incidence of SE-IOP was analysed using exact Poisson tests and survival analysis. The time course of IOP was evaluated with linear mixed effect modelling. In total, 6 treated eyes (2.38% incidence per eye-year) and 9 fellow eyes (3.58% incidence per eye-year) developed SE-IOP, and survival analysis showed no statistically significant difference (p = 0.43). Furthermore, the incidence of SE-IOP did not differ between the three anti-VEGF groups. Comparing the injected eyes of patients under 70 years to those of patients over 70 years, there was a statistically significant difference in survival without SE-IOP (incidence of 16.7% vs 0.7%, respectively, p < 0.0001). Intravitreal anti-VEGF injections were not associated with sustained elevation of IOP. These results do not support the claim that repeated anti-VEGF injections could elevate IOP.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the incidence of sustained elevation of intraocular pressure (SE-IOP) associated with intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) bevacizumab and aflibercept in patients with wet age-related macular degeneration (wAMD).
METHODS
METHODS
A retrospective cohort study consisting of 120 eyes from 120 patients with anti-VEGF treatment for wAMD. Three different anti-VEGF groups were considered: i) 71 cases receiving bevacizumab only, ii) 49 cases receiving bevacizumab before switch to aflibercept, iii) 49 cases after switch to aflibercept. 120 uninjected fellow eyes served as controls. SE-IOP was defined as an increase from baseline ≥5 mmHg on 2 consecutive follow-up visits. The incidence of SE-IOP was analysed using exact Poisson tests and survival analysis. The time course of IOP was evaluated with linear mixed effect modelling.
RESULTS
RESULTS
In total, 6 treated eyes (2.38% incidence per eye-year) and 9 fellow eyes (3.58% incidence per eye-year) developed SE-IOP, and survival analysis showed no statistically significant difference (p = 0.43). Furthermore, the incidence of SE-IOP did not differ between the three anti-VEGF groups. Comparing the injected eyes of patients under 70 years to those of patients over 70 years, there was a statistically significant difference in survival without SE-IOP (incidence of 16.7% vs 0.7%, respectively, p < 0.0001).
CONCLUSION
CONCLUSIONS
Intravitreal anti-VEGF injections were not associated with sustained elevation of IOP. These results do not support the claim that repeated anti-VEGF injections could elevate IOP.
Identifiants
pubmed: 34454473
doi: 10.1186/s12886-021-02076-1
pii: 10.1186/s12886-021-02076-1
pmc: PMC8399828
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antibodies, Monoclonal, Humanized
0
Recombinant Fusion Proteins
0
Vascular Endothelial Growth Factor A
0
aflibercept
15C2VL427D
Bevacizumab
2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
312Informations de copyright
© 2021. The Author(s).
Références
Ophthalmology. 2019 Jan;126(1):55-63
pubmed: 30077616
Retina. 2018 Oct;38(10):2088-2095
pubmed: 28841584
Ophthalmic Res. 2016;56(1):30-4
pubmed: 27046391
J Curr Glaucoma Pract. 2017 May-Aug;11(2):63-66
pubmed: 28924341
Ophthalmology. 2018 May;125(5):676-682
pubmed: 29336897
PLoS One. 2016 Sep 01;11(9):e0161332
pubmed: 27584577
J Glaucoma. 2014 Sep;23(7):446-8
pubmed: 23632401
Ophthalmology. 2015 Sep;122(9):1802-10
pubmed: 26025097
Am J Ophthalmol. 2012 Feb;153(2):209-213.e2
pubmed: 22264944
Rom J Ophthalmol. 2017 Jul-Sep;61(3):207-211
pubmed: 29450400
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):493-497
pubmed: 28906084
Acta Ophthalmol. 2012 Feb;90(1):e25-30
pubmed: 21958440
BMC Ophthalmol. 2016 May 31;16:69
pubmed: 27245159
Sci Rep. 2020 Aug 6;10(1):13248
pubmed: 32764619
Curr Opin Ophthalmol. 2019 Jan;30(1):56-62
pubmed: 30489361
J Curr Glaucoma Pract. 2017 Jan-Apr;11(1):3-7
pubmed: 28138211
Angiogenesis. 2012 Jun;15(2):171-85
pubmed: 22302382
Am J Ophthalmol. 2014 Aug;158(2):319-327.e2
pubmed: 24814167
Sci Rep. 2016 Dec 21;6:39301
pubmed: 28000707
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5346-52
pubmed: 18515571
Retina. 2012 Jul;32(7):1295-301
pubmed: 22466465
Indian J Ophthalmol. 2016 Sep;64(9):643-647
pubmed: 27853011
J Ophthalmol. 2020 Jan 20;2020:7462098
pubmed: 32051764
Semin Ophthalmol. 2013 May;28(3):126-30
pubmed: 23631423
Can J Ophthalmol. 2007 Dec;42(6):807-11
pubmed: 18026202
Sci Rep. 2019 Sep 13;9(1):13264
pubmed: 31519960